BrainsWay reported first-quarter 2026 revenue of $15.5 million, up roughly 35% year over year, and net income of $2.3 million — more than double the prior-year figure. The company shipped a record 117 Deep TMS systems in the quarter and reiterated full-year 2026 revenue guidance of $66–68 million.
Adjusted EBITDA more than doubled year over year to $2.8 million, and remaining performance obligations grew 25% to roughly $75 million, signaling a strengthening backlog and deeper enterprise-account relationships. The record shipment volume reflects strong demand for BrainsWay's Deep TMS technology, which holds FDA clearances for major depressive disorder (including anxious depression), OCD, and smoking addiction.
The quarter also coincided with expanding payer coverage for the company's accelerated SWIFT protocol.
For clinics, BrainsWay's growth points to accelerating adoption of Deep TMS and its accelerated protocols across the U.S. market.
Source
Reporting based on coverage from StockTitan. This article is editorial summary intended for general information; it is not medical advice.
